STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...
Medscape2h
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...
Medindia4d
STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), now available in the United States
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Morningstar4d
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...
Managed Healthcare Executive3d
Stelara Biosimilar Steqeyma Launches at 85% Discount
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
The Pharma Letter3d
Steqeyma, a biosimilar to Stelara, now available in the USA
South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
Chosunbiz4d
Celltrion launches Steqeyma autoimmune treatment in U.S. market
Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...
Lumicera Secures Purchase Agreement for Stelara® Biosimilar, Delivering Major Cost Savings
Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced ...